Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
Life Science Compliance Update
Are the Safe Harbors Still Safe? – OIG Issues Final Rule
The Department of Health and Human Services Office of Inspector General published a final rule, after considering various…
Valeant and Philidor Controversy Comes to a Head
Valeant Pharmaceuticals, Inc. has had quite the year - they have been under scrutiny since October 2015. However, in November…
2017 Trending Towards a Banner Year for Industry Compliance
There are strong indications that 2017 is already trending towards a banner year for industry compliance, including most…
Anti-corruption: All roads lead to enforcement
Amy Greenstein, Senior Consultant and Veronique Monjardet, Polaris
When it comes to corruption, Life Sciences companies…
Product Price Hikes – When Business and Compliance Collide
2016 was the year of the price increase, as leading industry players experienced significant public outrage over what appeared to…
Avoiding the Patient Assistance Program Spotlight
In efforts to understand the rising cost of some drugs, Patient Assistance programs, particularly independent…
Not All Discounts Are Equal: Evaluating When Discounts May Be Construed as…
Discounts within the health care industry are historically viewed as not being subject to the U.S. Federal Anti-Kick Back Statutes…
Nursing Facilities & Kickbacks – Is the DOJ Shifting Away from…
DOJ may have a new focus for Anti-Kickback Statute violations: care facilities and their owners. This year alone, at least two…
Co-Payment & Deductible Waivers as Illegal Inducements
Health insurance providers and out-of-network providers, have found themselves in murky water by providing waivers of co-payments,…
Planning for the Future – HHS OIG’s 2017 Work Plan
Health and Human Services Office of Inspector General has released their 2017 Work Plan. The updated work plan includes some new…